Pfizer To Become Largest Pharma In Japan After Wyeth Merger
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Pfizer Japan says upon Pfizer's expected merger with Wyeth later this year, it will become the largest pharmaceutical company in Japan, surpassing Takeda Pharmaceutical
You may also be interested in...
Despite A Wide Retreat From Discovery Research By Multinationals In Japan, Some Are Staying Put (Part 2 Of 3)
Countering the rush out of Japan's discovery research sector, a few global pharmaceutical corporations are maintaining early research operations or even expanding their presence in this area.
Despite A Wide Retreat From Discovery Research By Multinationals In Japan, Some Are Staying Put (Part 2 Of 3)
Countering the rush out of Japan's discovery research sector, a few global pharmaceutical corporations are maintaining early research operations or even expanding their presence in this area.
Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
Pfizer management, more bullish than the Street on long-term revenue forecasts for the combination of Pfizer and Wyeth, assured investors that incremental growth opportunities will emerge from the mega merger during a follow-up meeting with investors Jan. 27